Healthcare
Dianthus Therapeutics, Inc.(DNTH)
Live Price
Offline$82.24
+7.57% today
1Y Change
+349.89%
Window
Jun 25, 2025 โ Jun 15, 2026
- Market Cap
- $3.47B
- Revenue Growth
- -67.3%
- EPS Growth
- -64.7%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 25, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Dianthus Therapeutics, Inc. (DNTH) is a Healthcare stock with a market cap of $3.47B and listed on NASDAQ. The stock last traded around $82.23 and up 349.9% across the available one-year price window (Jun 25, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of -67.3%, EPS growth of -64.7%, a dividend yield of 0.0%. What stands out right now is revenue -67.3%, EPS -64.7%, free cash flow -65.1% with operating margin -21911.7% and ROIC -15.8%. Valuation already assumes a fairly strong business story at price/sales 3970.9. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines DNTH price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-67.3% vs +7.6% peer median
Operating Margin
Below sector median
-21911.7% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 11, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -67.3% and EPS is at -64.7%, with operating margin around -21911.7%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +3.1% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 11, 2026 | โ | -1.1% | -4.0% | -2.9% |
2026 Mar 9, 2026 | -45.9% | +9.7% | -1.6% | +8.8% |
2025 Nov 5, 2025 | -12.8% | +8.0% | +14.8% | +32.6% |
Benchmark Edge
DNTH vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
DNTH
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
DNTH Max Drawdown
-20.20%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for DNTH and SPY.
Company Overview
Dianthus Therapeutics, Inc.
NASDAQ Capital Market
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
- Leadership
- Marino Garcia
- IPO Date
- Jun 21, 2018
- Employees
- 78
- Street Address
- 7 Times Square
- Mailing
- New York City, NY, 10036
- Region
- New York City, NY, US
- Reporting Currency
- USD
- Investor Line
- 929-999-4055
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 3970.9
- Price/Book
- 2.8
Growth
- Revenue
- -67.3%
- EPS
- -64.7%
- Free Cash Flow
- -65.1%
Profitability
- Gross Margin
- 100.0%
- Operating Margin
- -21911.7%
- Net Margin
- -1297.0%
- ROE
- -1.8%
- ROIC
- -15.8%
Balance Sheet
- Debt/Equity
- 0.00
- Current Ratio
- 29.25
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.